PCRC_B51

A Randomized Phase III Clinical Trial Evaluating the Role of Post-mastectomy Chest Wall and Regional Nodal XRT and Post-lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery.

Key Eligibility:

* Clinically T1-3, N1 breast cancer (axillary involvement assessed by palpation, ultrasound, CT scan, MRI, PET scan) with pathologic confirmation at diagnosis.

* Patients may be any ER/PR or HER2 status and must have completed minimum 12 weeks neoadjuvant chemotherapy (anthracycline and/or taxane-based regimen).

* Adjuvant chemotherapy prior to initiation of Radiation Therapy is allowed.
Phase III
NCT01872975
Cancer, All Other
Breast
Benjamin Bridges , M.D.
NSABP (National Surgical Adjuvant Breast and Bowel Project)
Nikki Moxon

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.